Close Menu

GenomeWebinars

Thu
Mar
18
11:00 am2021
Sponsored by
Thermo Fisher Scientific

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Genome Webinar

Professor in Microbial Evolutionary Genomics, University of Birmingham
Infectious Disease Lead for the Milton Keynes Lighthouse Lab UK

Professor of Medicine at KU Leuven, Department of Microbiology and Immunology, Co-Director Infectious Diseases Centre
University Hospital of Leuven

Senior Medical Director
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures. For molecular diagnostic assays to serve in the management of viral transmission, they need to be designed anticipating the emergence of mutations.

This webinar will focus on the impact of emerging viral variants of SARS-CoV-2 on molecular diagnostic testing. In the first part of the session, Dr. Alan McNally will share how the B.1.1.7 variant was discovered in the United Kingdom, highlight the role played by a molecular diagnostic assay in its detection, and discuss design principles that aid in the development of effective and robust molecular diagnostic assays. In addition, Dr. McNally will discuss some of the clinical data associated with the B.1.1.7 strain as well as the importance of early identification of this variant of concern.

In the second part of the session, Dr. Emmanuel André will discuss his approach to identifying specific SARS-CoV-2 variants using a targeted mutation panel as a reflex test following a suspect clinical variant result. Dr. Andre will provide details about the mutation panel composition as well as the advantages of using this approach for wide-scale SARS-CoV-2 surveillance.

Learning Objectives:

  • Hear the story of detecting the B.1.1.7 variant (UK variant) from a world-leading epidemiologist.
  • Understand the importance of early detection of viral variants and the impact of emerging variants on global response efforts.
  • Learn about molecular diagnostic assay design principles to safeguard against unexpected false results due to mutations and the means to monitor assays as early indicators of emerging variants.
  • Learn about the S-gene advantage with B.1.1.7, the role of the S-gene dropout, and the value of a targeted mutation panel as a reflex tool as follow up for a suspected clinical variant.
Sponsored by

Professor, Epidemiology; Director, Infectious Disease Epidemiology Certificate Program
Columbia University Medical Center

Assistant Professor-Clinical in the Department of Pathology, Associate Director of the Molecular Pathology Laboratory
Ohio State University Wexner Medical Center

Senior Medical Director
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines. As such, global surveillance plays a central role in proactively managing pathogens such as SARS-CoV-2, the virus that causes COVID-19. 

Similarly, local genetic surveillance offers an opportunity to understand the evolution of the virus in the community and take actions to manage transmission and monitor evolution at the local level. Robust data about which strains are common, where they are spreading, how their symptoms differ, when new variants are emerging, and more can enable communities, states and countries to better prepare for their arrival. 

Vaccine and test manufacturers are guided by this information as well, cutting weeks or even months from any response they need to make. Genetic surveillance already exists on a large scale to enable scientists to determine which influenza strains are appropriate targets for each year’s flu vaccines, and a similar effort will be needed to make sense of SARS-CoV-2 and its evolving strains.

This webinar will focus on genetic surveillance of the emerging variants of SARS-CoV-2, provide an update on the trending variants, explain the risks of the rise of escape mutants, and outline best practices to establish both global and local surveillance programs, including technologies used for monitoring viral evolution, such as next-generation sequencing.

Learning Objectives:

  • Hear from a leading expert in infectious disease epidemiology regarding emerging variants of SARS-CoV-2.
  • Receive up-to-date information on the state of emerging variants, the impact of selective pressures, and the associated evolutionary advantage conferred to the virus.
  • Learn about best practices in standing up global and community surveillance efforts.
  • Hear from a thought leader in molecular pathology who harnessed his expertise in molecular genetics to contribute to surveillance efforts on a local level.
Sponsored by
Wed
Mar
31
1:00 pm2021
Sponsored by
MilliporeSigma

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Genome Webinar

VP, Product Development,
Mammoth Biosciences

Head of Strategic Implementation & Marketing – CMO,
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Mammoth Biosciences developed the test in response to the COVID-19 pandemic. The company was one of one of seven chosen to receive funding through the National Institutes of Health’s RADx program to support development and commercialization of the test.  

Tim Patno, vice president of product development at Mammoth Biosciences, will discuss Mammoth’s novel CRISPR-based technology as well as the company’s partnership with MilliporeSigma to manufacture its DETECTR BOOST SARS-CoV-2 Reagent Kit. Patno will discuss the steps Mammoth took to vet and choose a manufacturing partner within the context of commercializing a novel in vitro diagnostic.

Attendees will learn:

  • The basic technology and platform of the CRISPR-based SARS-CoV-2 DETECTR test.
  • The steps in the commercialization process of an IVD; from scope of work through to development, engineering, validation, and closing.
  • Advantages of working with a commercial partner to expedite kit development and launch.

 

Sponsored by